Male pattern baldness is not classified as a disease. It is medically termed androgenetic alopecia and categorized as an androgen-related disorder, a distinction that places it in the territory of inherited conditions driven by normal hormonal processes rather than illness or infection. It affects 30 to 50 percent of men by age 50, making it by far the most common form of hair loss in men. That prevalence alone hints at its nature: this is a genetically programmed response to hormones your body is supposed to produce, not a sign that something has gone wrong.
Why It’s Called a Disorder, Not a Disease
The difference matters. A disease typically involves a pathological process: tissue damage, immune malfunction, infection. Male pattern baldness involves none of these. Instead, it’s a predictable outcome of how certain hair follicles respond to dihydrotestosterone (DHT), a hormone derived from testosterone. Your body converts testosterone into DHT as part of normal metabolism. The problem isn’t that DHT exists or that your body produces too much of it. The problem is that some follicles, based on your genetic makeup, are sensitive to it.
When DHT binds to receptors in these susceptible follicles, it gradually shrinks them. Each growth cycle produces a thinner, shorter hair until the follicle eventually produces only fine, nearly invisible peach fuzz. This process, called follicle miniaturization, is the hallmark of androgenetic alopecia. The follicle itself isn’t destroyed. It’s progressively downsized, which is why early treatment can sometimes reverse the change.
The Genetics Behind It
Genetic predisposition is the single biggest factor determining whether you’ll lose your hair. Research published in the American Journal of Human Genetics identified the androgen receptor gene, located on the X chromosome, as the primary genetic driver of early-onset baldness. Because you inherit your X chromosome from your mother, the maternal line plays a particularly significant role. Researchers estimate that variations in this single gene account for roughly 46 percent of the genetic risk for early hair loss.
That still leaves more than half the genetic picture unaccounted for. The condition is polygenic, meaning multiple genes across different chromosomes contribute. This explains why hair loss patterns sometimes resemble your father’s side of the family despite the strong X-chromosome link. The interplay of maternal and paternal genes creates the wide spectrum of balding patterns and timelines men experience.
How Common It Actually Is
The numbers are striking. In the United States, a survey found that 53 percent of men aged 40 to 49 already had moderate or severe hair loss. An Australian study of nearly 1,400 men showed vertex or full baldness rising from 31 percent in men aged 40 to 55, up to 53 percent by ages 65 to 69. In Singapore, where researchers tracked men across the full age range, prevalence climbed from 32 percent in men aged 17 to 26 all the way to 100 percent after age 80.
These figures reinforce the point: if every man who lives long enough will experience some degree of it, calling it a disease stretches the definition past usefulness. It’s closer to graying hair in its universality, even though its cosmetic and psychological effects can be far more significant.
Links to Other Health Conditions
While baldness itself isn’t a disease, it may serve as a signal worth paying attention to. The same androgen activity driving hair loss has been linked to cardiovascular and prostate health. Research has found that men who begin losing hair at a younger age face a higher risk of prostate cancer, with frontal balding showing a stronger association than vertex (crown) balding. Overall balding was associated with a more than twofold increase in risk for high-grade prostate disease.
Cardiovascular connections have also been documented. There is general agreement that androgenetic alopecia is associated with heart attacks and other cardiovascular problems, though researchers haven’t reached consensus on which balding pattern carries the most risk. None of this means baldness causes these conditions. Rather, the shared androgen pathways suggest that early, significant hair loss could be a visible marker of broader hormonal activity worth discussing with a doctor.
The Psychological Weight
The fact that baldness isn’t technically a disease doesn’t diminish its real impact. More than 25 percent of men with androgenetic alopecia describe the hair loss as extremely upsetting, and 65 percent report modest to moderate emotional distress. In one study, 88 percent of participants said hair loss negatively affected their daily life, 75 percent reported a hit to their self-esteem, and 50 percent experienced social problems because of it. Anxiety is particularly common in men with hair loss, affecting 41 percent in one study compared to lower rates in control groups without hair loss.
These effects hit hardest when hair loss starts early and when men are single. Younger age, single marital status, and a desire for medical treatment are all associated with greater psychological distress. Even after six months of treatment, more than half of participants in one study said hair loss still affected their social lives. The gap between “not a disease” and “not a problem” is enormous.
What Treatment Looks Like
Two main treatments have strong evidence behind them. The first is a topical solution applied directly to the scalp (minoxidil), which works by stimulating blood flow to follicles and extending the growth phase of hair. In a study of 904 men, 84.3 percent reported some degree of regrowth after one year of use. The second is an oral medication (finasteride) that blocks the conversion of testosterone to DHT. A large Japanese study following over 3,000 men for three years found that about 47 percent experienced moderate to significant regrowth, while another 39.5 percent saw slight improvement.
Combining both approaches appears to work better than either alone, with one study showing an 84 percent success rate in maintaining good hair density. Other options include low-level laser therapy, which can increase terminal hair count when used three times per week, and platelet-rich plasma injections given monthly for three sessions and then every three to six months for maintenance.
One important detail: if you start minoxidil, expect a temporary increase in shedding during the first weeks. This is a normal part of the process and not a reason to stop. Doctors generally consider someone a non-responder only after six months of continuous use without improvement.
How Progression Is Measured
Doctors use the Norwood-Hamilton scale to classify where you fall on the balding spectrum. It runs from Type I (minimal or no hairline recession) through Type VII and VIII (extensive loss leaving only a horseshoe-shaped band of hair around the sides and back). The early stages, Types II and III, involve increasingly noticeable recession at the temples. By Type IV, the hairline has receded significantly past the midpoint of the scalp. Type V and beyond involve merging of the frontal and crown bald spots into larger areas of loss.
Where you fall on this scale matters for treatment decisions. Earlier stages respond better to medication because more follicles are still in the miniaturization process rather than fully dormant. By the later stages, surgical hair transplantation becomes the primary option for restoring coverage, since medication works best on follicles that are shrinking but still active.